Oxford Textbook of Rheumatoid Arthritis

Oxford University Press
  • erschienen am 18. September 2020
  • |
  • 576 Seiten
E-Book | ePUB mit Adobe-DRM | Systemvoraussetzungen
978-0-19-256711-6 (ISBN)
This brand new textbook of rheumatoid arthritis (RA) is an important addition to the Oxford Textbooks in Rheumatology series, and provides a comprehensive overview of both the scientific and clinical aspects of the disease. Divided into eight sections - from the history, diagnosis, and epidemiology of the disease, through the pathogenesis, clinical presentation, and assessment to treatments and management strategies, both drug- and non-drug based - each chapter is written by leading clinicians and scientists in the field to deliver a contemporary view of RA. During the past two decades there have been revolutionary changes in the understanding and management of rheumatoid arthritis, in particular the development of biological treatments. This has had wide-ranging effects on almost all aspects of treatment, from effectiveness and intensity to the nature and the cost. Providing a comprehensive account of the modern ideas about the disease, the Oxford Textbook of Rheumatoid Arthritis is a key new addition to the literature, with each chapter providing a detailed background, key recent advances, and areas of doubt and future developments. Featuring over 170 photographs, radiological images, and clinical charts to aid both diagnosis and illustrate the rationale behind key scientific studies, this new title will prove an indispensable resource for specialist rheumatologists, trainees in rheumatology, and other members of the multi-disciplinary team.
  • Englisch
  • Oxford
  • |
  • Großbritannien
  • 74,79 MB
978-0-19-256711-6 (9780192567116)
weitere Ausgaben werden ermittelt
David L. Scott is Professor of Clinical Rheumatology at King's College London. He trained in medicine and rheumatology in Leeds and Birmingham and subsequently held a fellowship at St Bartholomew's Hospital in London. His current academic focus spans the outcomes of rheumatoid arthritis and the impact of intensive treatment in improving outcomes in clinical trials. James Galloway is Senior Lecturer in Rheumatology at King's College London and Honorary Consultant Rheumatologist at King's College Hospital. After training in medicine and rheumatology in Bristol and Manchester he held a fellowship at the Arthritis Research UK Epidemiology Unit in Manchester. His current academic focus is on large observational studies of arthritis and treatment risks including infections Andrew Cope is Arthritis Research UK Professor of Rheumatology at King's College London and Honorary Consultant Rheumatologist at Guy's and St Thomas's Hospital. After training in medicine and rheumatology in London he held fellowships at the Kennedy Institute of Rheumatology and Stanford University. His current academic focus spans laboratory studies, clinical trials and observational studies with an emphasis on understanding the immunobiology of inflammatory arthritis. Arthur Pratt is Clinical Fellow in the Institute of Cellular Medicine and Honorary Consultant Rheumatologist at the Freeman Hospital in Newcastle. He trained in medicine and rheumatology in Leeds and Newcastle. Subsequently he was a training fellow and National Institute for Health Clinical Lecturer at Newcastle University. His current academic focus is clinical and laboratory assessments and predictors in early inflammatory arthritis. Vibeke Strand is Adjunct Clinical Professor, in the Division of Immunology and Rheumatology at Stanford University. She is a clinical rheumatologist and acts as a consultant in biopharmaceutics, clinical research, and regulatory affairs to many pharmaceutical and biotech companies. After graduating from Swarthmore College she trained in medicine and rheumatology at University of California San Francisco School of Medicine. Her current academic focus spans clinical trial design, development of outcome measures with an emphasis on patient reported outcomes and regulatory strategies leading to approval of new agents for treatment of autoimmune diseases. She gives particular emphasis to translating basic research findings into rationally designed clinical trials, evaluating their results and helping patients access new treatments.
  • Cover
  • Series
  • Oxford Textbook of Rheumatoid Arthritis
  • Copyright
  • Contents
  • Contributors
  • Symbols and abbreviations
  • Section 1 History, diagnosis, and epidemiology
  • 1 The history of rheumatoid arthritis
  • 2 Diagnosis
  • 3 The descriptive epidemiology of rheumatoid arthritis
  • 4 Modifiable and other risk factors for rheumatoid arthritis: A basis for prevention and better therapy
  • Section 2 Pathogenesis
  • 5 Genetics and epigenetics of rheumatoid arthritis
  • 6 Dysregulation of synovial fibroblasts in rheumatoid arthritis
  • 7 Autoantibodies in rheumatoid arthritis
  • 8 Dendritic cells and T cells in rheumatoid arthritis
  • 9 Mechanisms of bone and cartilage destruction
  • 10 Cytokines and other mediators
  • Section 3 Clinical presentation
  • 11 Clinical features of rheumatoid arthritis
  • 12 Pre-?rheumatoid arthritis
  • 13 Non-?articular manifestations of rheumatoid arthritis
  • 14 Comorbidity in rheumatoid arthritis
  • Section 4 Disease assessment
  • 15 Disease activity assessment in rheumatoid arthritis
  • 16 Synovial biopsies
  • 17 Radiography in rheumatoid arthritis
  • 18 Ultrasound in rheumatoid arthritis
  • 19 Magnetic resonance imaging in rheumatoid arthritis
  • Section 5 Impact on life
  • 20 Patient physical function in rheumatoid arthritis
  • 21 Fatigue
  • 22. Health economics of rheumatoid arthritis
  • 23 Rheumatoid arthritis and work
  • Section 6 Non-?drug treatments
  • 24 Physical activity and exercise
  • 25 Foot health
  • 26 Occupational therapy
  • 27 Self-?management: A patient's perspective
  • Section 7 Drug treatments
  • 28 Analgesics, opioids, and NSAIDs
  • 29 Glucocorticoids
  • 30 Conventional disease-?modifying drugs
  • 31 Tumour necrosis factor inhibitors
  • 32 Interleukin-?6 inhibitors
  • 33 B-?cell therapies
  • 34 Biosimilars
  • 35 Immunogenicity in response to biologic agents
  • 36 The use of JAK inhibitors in the treatment of rheumatoid arthritis
  • 37 Combination therapy in rheumatoid arthritis
  • 38 Translation of new therapies: From bench to bedside
  • 39 Adverse events in clinical studies in rheumatoid arthritis
  • Section 8 Management and outcomes
  • 40 Prevention of rheumatoid arthritis
  • 41 Treatment targets and remission
  • 42 Clinical outcomes
  • 43 Clinical recommendations
  • 44 European biologics registers
  • 45 Voluntary patient registries

Dateiformat: ePUB
Kopierschutz: Adobe-DRM (Digital Rights Management)


Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat ePUB ist sehr gut für Romane und Sachbücher geeignet - also für "fließenden" Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Bitte beachten Sie bei der Verwendung der Lese-Software Adobe Digital Editions: wir empfehlen Ihnen unbedingt nach Installation der Lese-Software diese mit Ihrer persönlichen Adobe-ID zu autorisieren!

Weitere Informationen finden Sie in unserer E-Book Hilfe.

Download (sofort verfügbar)

132,99 €
inkl. 7% MwSt.
Download / Einzel-Lizenz
ePUB mit Adobe-DRM
siehe Systemvoraussetzungen
E-Book bestellen